We are analyzing https://link.springer.com/article/10.1007/s00280-008-0902-8.

Title:
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib | Cancer Chemotherapy and Pharmacology
Description:
Purpose The epidermal growth factor receptor (EGFR), an N-glycosylated transmembrane protein, is the target of erlotinib, an orally bioavailable agent approved for treatment of patients with non-small cell lung cancer (NSCLC). In this study, we examined whether inhibition of EGFR N-glycosylation and stimulation of endoplasmic reticulum (ER) stress by tunicamycin enhances erlotinib-induced growth inhibition in NSCLC cell lines. Methods We examined the effects of tunicamycin and erlotinib on cytotoxicity of erlotinib-sensitive and resistant NSCLC cell lines, as well its effects on apoptotic pathways and on EGFR activation and subcellular localization. Results A minimally cytotoxic concentration of tunicamycin (1 μM) resulted in~2.6–2.9 fold and~6.8–13.5 fold increase in erlotinib-induced antiproliferative effects in sensitive (H322 and H358) and resistant cell lines (A549 and H1650), respectively. We found that tunicamycin generated an aglycosylated form of 130 kDa EGFR. Tunicamycin additionally affected EGFR activation and subcellular localization. Interestingly, the combination of tunicamycin and erlotinib caused more inhibitory effect on EGFR phosphorylation than that of erlotinib alone. Moreover, the combination induced apoptosis in H1650 cells through induction of CHOP expression, activation of caspase-12 and caspase-3, cleavage of PARP and bak, and down-regulation of anti-apoptotic proteins bcl-xL and survivin. Conclusions Overall, our data demonstrate that tunicamycin significantly enhances the susceptibility of lung cancer cells to erlotinib, particularly sensitizing resistant cell lines to erlotinib, and that such sensitization may be associated with activation of the ER stress pathway and with inhibition of EGFR N-glycosylation.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,603,974 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

article, google, scholar, cancer, pubmed, cas, cell, lung, growth, receptor, epidermal, factor, cells, erlotinib, egfr, tunicamycin, nonsmall, human, inhibition, activation, apoptosis, biol, res, clin, stress, enhances, tyrosine, kinase, oncol, privacy, cookies, function, content, ling, perezsoler, lines, access, chem, data, information, publish, search, nglycosylation, nsclc, study, endoplasmic, reticulum, effects, pathways, response,

Topics {✒️}

anti-apoptotic proteins bcl-xl month download article/chapter missak haigentz jr small-cell lung cancer er stress-induced apoptosis tunicamycin-induced er stress n-glycosylated transmembrane protein related subjects n-linked oligosaccharide chains erlotinib-induced antiproliferative effects article cancer chemotherapy lung cancer cells nsclc cell lines egfr-tki rechallenge lung cancer er full article pdf tunicamycin significantly enhances tunicamycin enhances sensitivity combination induced apoptosis resistant cell lines tunicamycin enhances susceptibility privacy choices/manage cookies er stress pathway receptor glycosylation pathways programmed cell death enhanced cytotoxicity induced sh-sy5y cells cell cycle arrest n-linked glycosylation egfr n-glycosylation growth factor phase iii trial article ling tyrosine phosphorylation sk-n-sh european economic area minimally cytotoxic concentration check access heterologous signaling systems endogenous akt/iaps mek1/erk pathways mevalonate pathway inhibits mevalonic acid depletion albert einstein college health grants ca91784 instant access lung cancer perez-soler conditions privacy policy vascular endothelial cadherin

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib
         description:The epidermal growth factor receptor (EGFR), an N-glycosylated transmembrane protein, is the target of erlotinib, an orally bioavailable agent approved for treatment of patients with non-small cell lung cancer (NSCLC). In this study, we examined whether inhibition of EGFR N-glycosylation and stimulation of endoplasmic reticulum (ER) stress by tunicamycin enhances erlotinib-induced growth inhibition in NSCLC cell lines. We examined the effects of tunicamycin and erlotinib on cytotoxicity of erlotinib-sensitive and resistant NSCLC cell lines, as well its effects on apoptotic pathways and on EGFR activation and subcellular localization. A minimally cytotoxic concentration of tunicamycin (1 μM) resulted in~2.6–2.9 fold and~6.8–13.5 fold increase in erlotinib-induced antiproliferative effects in sensitive (H322 and H358) and resistant cell lines (A549 and H1650), respectively. We found that tunicamycin generated an aglycosylated form of 130 kDa EGFR. Tunicamycin additionally affected EGFR activation and subcellular localization. Interestingly, the combination of tunicamycin and erlotinib caused more inhibitory effect on EGFR phosphorylation than that of erlotinib alone. Moreover, the combination induced apoptosis in H1650 cells through induction of CHOP expression, activation of caspase-12 and caspase-3, cleavage of PARP and bak, and down-regulation of anti-apoptotic proteins bcl-xL and survivin. Overall, our data demonstrate that tunicamycin significantly enhances the susceptibility of lung cancer cells to erlotinib, particularly sensitizing resistant cell lines to erlotinib, and that such sensitization may be associated with activation of the ER stress pathway and with inhibition of EGFR N-glycosylation.
         datePublished:2009-01-08T00:00:00Z
         dateModified:2009-01-08T00:00:00Z
         pageStart:539
         pageEnd:548
         sameAs:https://doi.org/10.1007/s00280-008-0902-8
         keywords:
            Tunicamycin
            Erlotinib
            EGFR TKI
            ER stress
            Human NSCLC cells
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig6_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:64
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yi-He Ling
               affiliation:
                     name:Albert Einstein College of Medicine
                     address:
                        name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tianhong Li
               affiliation:
                     name:Albert Einstein College of Medicine
                     address:
                        name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Roman Perez-Soler
               affiliation:
                     name:Albert Einstein College of Medicine
                     address:
                        name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Missak Haigentz
               affiliation:
                     name:Albert Einstein College of Medicine
                     address:
                        name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib
      description:The epidermal growth factor receptor (EGFR), an N-glycosylated transmembrane protein, is the target of erlotinib, an orally bioavailable agent approved for treatment of patients with non-small cell lung cancer (NSCLC). In this study, we examined whether inhibition of EGFR N-glycosylation and stimulation of endoplasmic reticulum (ER) stress by tunicamycin enhances erlotinib-induced growth inhibition in NSCLC cell lines. We examined the effects of tunicamycin and erlotinib on cytotoxicity of erlotinib-sensitive and resistant NSCLC cell lines, as well its effects on apoptotic pathways and on EGFR activation and subcellular localization. A minimally cytotoxic concentration of tunicamycin (1 μM) resulted in~2.6–2.9 fold and~6.8–13.5 fold increase in erlotinib-induced antiproliferative effects in sensitive (H322 and H358) and resistant cell lines (A549 and H1650), respectively. We found that tunicamycin generated an aglycosylated form of 130 kDa EGFR. Tunicamycin additionally affected EGFR activation and subcellular localization. Interestingly, the combination of tunicamycin and erlotinib caused more inhibitory effect on EGFR phosphorylation than that of erlotinib alone. Moreover, the combination induced apoptosis in H1650 cells through induction of CHOP expression, activation of caspase-12 and caspase-3, cleavage of PARP and bak, and down-regulation of anti-apoptotic proteins bcl-xL and survivin. Overall, our data demonstrate that tunicamycin significantly enhances the susceptibility of lung cancer cells to erlotinib, particularly sensitizing resistant cell lines to erlotinib, and that such sensitization may be associated with activation of the ER stress pathway and with inhibition of EGFR N-glycosylation.
      datePublished:2009-01-08T00:00:00Z
      dateModified:2009-01-08T00:00:00Z
      pageStart:539
      pageEnd:548
      sameAs:https://doi.org/10.1007/s00280-008-0902-8
      keywords:
         Tunicamycin
         Erlotinib
         EGFR TKI
         ER stress
         Human NSCLC cells
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0902-8/MediaObjects/280_2008_902_Fig6_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:64
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yi-He Ling
            affiliation:
                  name:Albert Einstein College of Medicine
                  address:
                     name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tianhong Li
            affiliation:
                  name:Albert Einstein College of Medicine
                  address:
                     name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Roman Perez-Soler
            affiliation:
                  name:Albert Einstein College of Medicine
                  address:
                     name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Missak Haigentz
            affiliation:
                  name:Albert Einstein College of Medicine
                  address:
                     name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:64
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Albert Einstein College of Medicine
      address:
         name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
         type:PostalAddress
      name:Albert Einstein College of Medicine
      address:
         name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
         type:PostalAddress
      name:Albert Einstein College of Medicine
      address:
         name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
         type:PostalAddress
      name:Albert Einstein College of Medicine
      address:
         name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yi-He Ling
      affiliation:
            name:Albert Einstein College of Medicine
            address:
               name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
               type:PostalAddress
            type:Organization
      name:Tianhong Li
      affiliation:
            name:Albert Einstein College of Medicine
            address:
               name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
               type:PostalAddress
            type:Organization
      name:Roman Perez-Soler
      affiliation:
            name:Albert Einstein College of Medicine
            address:
               name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
               type:PostalAddress
            type:Organization
      name:Missak Haigentz
      affiliation:
            name:Albert Einstein College of Medicine
            address:
               name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
      name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
      name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
      name:Department of Oncology, Albert Einstein College of Medicine, Bronx, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(125)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.67s.

LINK . SPRINGER . COM {}